Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia.
DOI: 10.1038/s41372-021-01125-3; PMCID: PMC8184867
OBJECTIVE: To describe effectiveness of repeat dexamethasone for bronchopulmonary dysplasia (BPD) and to evaluate adverse effects on growth.
STUDY DESIGN: Retrospective study of infants treated with 1 or 2 courses of dexamethasone for BPD. Effectiveness was defined as successful step-down in respiratory support by end of treatment. Adverse effects on growth were analyzed and compared to untreated controls.
RESULTS: A total of 132 dexamethasone-treated infants were identified. In total, 52% (69/132) of infants treated with initial dexamethasone achieved step-down in respiratory support compared to 38% (20/52) of infants with repeat dexamethasone. Growth trajectory did not significantly differ among infants treated with 1 or 2 courses of dexamethasone compared with controls (weight: P = 0.23, length: P = 0.68, and head circumference: P = 0.77).
CONCLUSIONS: Repeat dexamethasone for BPD was less effective in weaning respiratory support compared to initial course. Changes in growth parameters to discharge were comparable between controls and infants treated with 1 or 2 dexamethasone courses.
Journal of perinatology : official journal of the California Perinatal Association
Cuna A, Quiqley A, Varghese K, et al. Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia. J Perinatol. 2021;41(8):1956-1962. doi:10.1038/s41372-021-01125-3